DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for common cold — screening already-approved drugs against its 24-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleCommon cold maps to a 24-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for common cold is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
adrenoceptor beta 3 (ADRB3) — ADRB3 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet aledrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 9IJE · 2.34 Å · ligand L-EPINEPHRINE (ALE). Experimental structure, not a prediction.
What the evidence adds up to
The common cold is caused by a large number of respiratory viruses, and all of these viruses may produce the illness complex recognised as the common cold. The disease fits an "iceberg concept" ranging from asymptomatic infection to severe illness and death. Factors that influence the incidence of colds include crowding, sociability, stress, smoking, alcohol, immune status, sex, age, sleep, season, chilling, nutrition, and exercise. The mechanism of symptoms is related to the innate immune response, and the host response to the virus, particularly pro-inflammatory cytokines, appears to be an important contributor to pathogenesis and an attractive target for new interventions.
Currently available treatments for the common cold have limited efficacy against specific symptoms. A 2002 review of treatment modalities found that antibiotics, antihistamines, decongestants, anticholinergics, mast cell stabilisers, herbal medicines, zinc, and steam therapy have been studied, with studies both supporting and refuting their effectiveness. Newer antiviral agents evaluated in clinical trials may provide a starting point for development of effective therapies, but no concrete survival or response rates are reported in these abstracts. The 1941 paper draws an analogy between respiratory tract invasion and war, emphasising the importance of the nasal mucous blanket and ciliated epithelium as a first line of defence, and noting that dry hot atmosphere, metabolic disturbances, and dietary insufficiencies can break down these defences.
No vaccine is yet available, and the morbidity associated with the common cold remains a topic of discussion. The 1967 paper from the Medical Research Council Common Cold Research Unit provides no specific treatment data. The 2011 paper notes that therapies should be selected to treat the specific symptoms perceived as most bothersome by the patient, but does not report any new drug efficacy. What is still missing is a clear understanding of how to target the host inflammatory response without disrupting necessary immune functions, and the funding and trial designs needed to test antiviral or anti-inflammatory agents against the many different viruses that cause colds. Patient stratification by virus type or symptom profile has not been achieved in a practical treatment setting.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Frontiers in Allergy · 2023 · 35 citations · open access
Common cold
AbstractThe common cold is a unique human disease, as it is arguably the most common disease and because of the large number of respiratory viruses causing colds it is one of the most complex of human diseases. This review discusses the respiratory viruses and notes that all these viruses may cause the illness complex recognised as the common cold. The common cold is discussed as part of the "iceberg concept" of disease which ranges from asymptomatic infection to severe illness and death. The factors influencing the incidence of colds are discussed: crowding and sociability, stress, smoking and alcohol, immune status, sex, age, sleep, season, chilling, nutrition and exercise. The mechanism of symptoms related to the innate immune response is explained and symptomatic treatments are tabulated. Morbidity associated with common cold is discussed and possible vaccines.
AbstractJournal Article COMMON COLDS AND RELATED DISEASES Get access D. A. J. TYRRELL, M.D. F.R.C.P. D. A. J. TYRRELL, M.D. F.R.C.P. Medical Research Council, Common Cold Research Unit, Harvard HospitalSalisbury, Wiltshire Search for other works by this author on: Oxford Academic PubMed Google Scholar British Medical Bulletin, Volume 23, Issue 2, May 1967, Pages 124–128, https://doi.org/10.1093/oxfordjournals.bmb.a070531 Published: 01 May 1967
Archives of Otolaryngology - Head and Neck Surgery · 1941 · 4 citations
PROPHYLAXIS OF THE COMMON COLD
AbstractThere can be drawn a fairly apt analogy between war and the invasion of the tissues of the upper respiratory tract by the organisms which give rise to the common cold. In accordance with this analogy, the invading forces in infections of the upper respiratory tract are the many pathogenic bacteria associated with respiratory disease. The defenses of the nose against such invasion are twofold—the front line, which consists of the mucous blanket and ciliated epithelium of the nasal mucosa, and the second line, represented in the natural immune responses of the tissues to such bacteria. The importance of maintaining an adequate first line of defense has been stressed by Proetz,<sup>1</sup>Hilding,<sup>2</sup>Lierle<sup>3</sup>and others. They have pointed out the factors which tend to break down these defense mechanisms. The fifth column activities of a dry hot atmosphere, of metabolic disturbances, of dietary insufficiencies and the like are well known
Current Opinion in Otolaryngology & Head & Neck Surgery · 2002 · 1 citations
Advances in treating the common cold: an update for otolaryngologists
AbstractEven though the common cold is one of the most common infections experienced by modern society, its origins, pathophysiology, and treatment remain poorly understood by the lay person and by many medical professionals. This article presents and discusses the pathophysiology of these viral infections and numerous studies that support or refute the effectiveness of several common treatment modalities, including antibiotics, antihistamines and decongestants, anticholinergics, mast cell stabilizers, herbal medicines, zinc, and steam therapy. This article also reviews several newer antiviral agents that have recently been evaluated in clinical trials and that may ultimately provide a starting point for development of effective cold therapies.
Psychological Science and Education psyedu.ru · 2011 · 0 citations · open access
Strategic Competence and Linguistic Identity Development of a Bilingual
AbstractRecent studies suggest that the host response to the virus is an important contributor to the pathogenesis of the common cold. Inflammatory mediators, especially the pro-inflammatory cytokines, appear to be an important component of this response and present an attractive target for new interventions for common cold therapies. Currently available treatments for the common cold have limited efficacy against specific symptoms. These therapies should be selected to treat the specific symptoms that are perceived to be the most bothersome by the patient.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
